Aduro Biotech (ADRO)

[BajaWizard]

Don't know, but, some good upgrading.

Cheers


( http://www.tickerreport.com/banking-finance/1035228/aduro-biotech-pt-lowered-to-68-00-adro/)

"Ticker Report"


Aduro BioTech PT Lowered to $68.00 (ADRO)

Posted by Shane Hupp on Nov 24th, 2015 // No Comments
Share on StockTwits

Aduro BioTech logoAduro BioTech (NASDAQ:ADRO) had its price objective lowered by research analysts at Roth Capital from $74.00 to $68.00 in a research report issued on Tuesday, MarketBeat reports. The firm currently has a “buy” rating on the stock. Roth Capital’s price objective would suggest a potential upside of 113.57% from the company’s current price.

In other Aduro BioTech news, CEO Stephen T. Isaacs sold 25,000 shares of Aduro BioTech stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $27.54, for a total transaction of $688,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Gregory W. Schafer sold 26,470 shares of Aduro BioTech stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $28.15, for a total value of $745,130.50. Following the transaction, the chief operating officer now directly owns 34,279 shares of the company’s stock, valued at approximately $964,953.85. The disclosure for this sale can be found here.

Aduro BioTech (NASDAQ:ADRO) opened at 32.23 on Tuesday. The company’s market capitalization is $2.01 billion. The company’s 50-day moving average is $25.71 and its 200 day moving average is $26.66. Aduro BioTech has a one year low of $16.28 and a one year high of $49.25.

Aduro BioTech (NASDAQ:ADRO) last posted its earnings results on Monday, November 23rd. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The company earned $19.15 million during the quarter, compared to the consensus estimate of $15.80 million. Analysts predict that Aduro BioTech will post ($1.17) EPS for the current year.

A number of other research firms have also recently commented on ADRO. Oppenheimer began coverage on shares of Aduro BioTech in a research report on Monday, October 19th. They set an “outperform” rating and a $30.00 target price for the company. Canaccord Genuity reaffirmed a “buy” rating and set a $43.00 price objective on shares of Aduro BioTech in a research report on Tuesday, August 11th. Zacks Investment Research upgraded Aduro BioTech from a “sell” rating to a “hold” rating in a report on Wednesday, October 14th. Leerink Swann assumed coverage on Aduro BioTech in a research note on Wednesday, August 19th. They set a $48.00 price objective on the stock. Finally, William Blair reiterated an “outperform” rating on shares of Aduro BioTech in a research note on Wednesday, September 9th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $45.80.

Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live, attenuated Listeria, GVAX and cyclic dinucleotides (NASDAQ:ADRO). Aduro’s lead program is an immunotherapy regimen combining Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy. Its pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX. CRS-207 is based on Aduro’s Listeria platform. ADU-623 is Aduro’s first clinical bivalent Listeria-based immunotherapy. ADU-214 is a bivalent Listeria-based immunotherapy that targets both mesothelin and an EGFR mutation. CDNs are small molecules that signal through STING and induce a potent immune response. STINGVAX is the combination of CDNs and GVAX.